top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video
Dr. Richardson Discusses New Directions in Multiple Myeloma
Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma. View now
Gina Columbus

Gina Columbus highlights the latest news in oncology in this week's OncLive News Network.

Publication Bottom Border
Border Publication
x